Ricki Fairley, Chief Executive Officer at Touch, The Black Breast Cancer Alliance, shared a post on LinkedIn:
“Huge News: The Standard of Care for Metastatic TNBC Just Changed—and It’s a Game Changer for Blessties.
For a long time, treating metastatic Triple Negative Breast Cancer (mTNBC) has been challenging. But this week, the National Comprehensive Cancer Network (NCCN) updated their guidelines for treating mTNBC to include better options!
- For PD-L1 Negative Metastatic TNBC Tumors: Trodelvy is now a preferred first-line treatment. This means you don’t have to “fail” other treatments first to get access to this advanced medicine.
- For PD-L1 Positive Metastatic TNBC Tumors: The combination of Trodelvy + Keytruda is now a preferred first-line option.
Why does this matter for the Black community? We know that Black women are nearly 3x more likely to be diagnosed with TNBC, and we are often diagnosed at later stages. 30% to 40% of Black women with metastatic breast cancer never make it to a second line of treatment.
This NCCN update changes the rules: It makes the most powerful, targeted science available as soon you are diagnosed with mTNBC.
At TOUCHBBCA, our mission is to make sure you aren’t just a “patient”, but the CEO of your own health.
If you or a loved one are facing a metastatic TNBC diagnosis, ask your doctor to adhere to the new NCCN guidelines. Knowledge is our superpower.
Thanks Gilead Sciences for this critical breakthrough to save lives!”
More posts featuring Ricki Fairley